ClinicalTrials.Veeva

Menu

Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency

The Chinese University of Hong Kong logo

The Chinese University of Hong Kong

Status

Withdrawn

Conditions

Coronary Bypass Graft Stenosis
Coronary Artery Disease
Hyperlipidemia
Dyslipidemias
Hypercholesterolemia
Bypass Graft Occlusion
Bypass Graft Stenosis
Coronary Artery Stenosis

Treatments

Radiation: Computed tomography coronary angiogram

Study type

Observational

Funder types

Other

Identifiers

NCT05393882
CRE Ref no. 2022.134

Details and patient eligibility

About

This single-centre cross-sectional study aims to ascertain the impact of dyslipidemia on long-term graft patency after coronary artery bypass grafting (CABG).

Full description

All consecutive patients who underwent CABG from 1st January 2007 to 31st December 2008 at the Prince of Wales Hospital were eligible for entry.

Graft patency will be determined by computed tomography coronary angiogram. The severity of stenosis will be classified by the Fitzgibbon classification system.

The levels of individual lipid profile subcomponents, namely LDL-C, high-density lipoprotein cholesterol (HDL-C), total cholesterol and triglycerides (TG) will be obtained. A plot of lipid profile subcomponent measurements against time will be compiled and the area under the curve is calculated to estimate gross exposure after CABG. Average lipid exposure is calculated by dividing the gross exposure by the number of days lapsed between the first and last lipid profile measurements.

The association between average cholesterol target attainment and graft patency will then be determined.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All consecutive patients on record who underwent coronary artery bypass graft surgery in 2007 and 2008

Exclusion criteria

  • Death
  • Single vessel LIMA-LAD anastomosis only
  • Concomitant valve and aortic procedures
  • Concomitant repair of post-infarct ventricular septal rupture
  • Defaulted follow-up
  • Informed consent cannot be obtained
  • Intermediate to high risk for contrast nephropathy, defined as estimated glomerular filtration rate less than 45 ml/min/1.73m2 or serum creatinine level <1.5 mg/dL (based on American College of Radiology criteria for diagnostic computed tomography risk)
  • Pregnancy

Trial contacts and locations

1

Loading...

Central trial contact

Randolph HL Wong, FRCS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems